MDRO tests for my lab and how the results become a surveillance report
Which tests a hospital laboratory runs for each multidrug resistant organism, what the infection control program needs back from them, and where the reporting work actually goes wrong.
8 min read
A hospital laboratory covers the main multidrug resistant organisms with three kinds of test: routine susceptibility testing on clinical isolates, phenotypic or molecular confirmation of the resistance mechanism (carbapenemase testing for CRE above all), and active surveillance screens such as MRSA nasal PCR. Most community labs already run the first and part of the second. The gap is rarely the bench test. It is turning the results into the MDRO counts by unit and quarter that infection control and NHSN reporting ask for.
This article is for the laboratory supervisor, microbiology lead or infection preventionist at a US community hospital who has been asked which MDRO tests the lab should offer and how the results will be reported. It covers the tests by organism, what an infection control program needs back from them, and the reporting side, which is where Antimicrobe sits. It does not replace your laboratory director, CLSI M100 or your state public health laboratory.
MDRO tests by organism
The organisms below are the ones the CDC NHSN MDRO and CDI module tracks (MRSA, VRE, cephalosporin resistant Klebsiella, CRE and multidrug resistant Acinetobacter) plus carbapenem resistant Pseudomonas aeruginosa, which most stewardship programs watch as well. The test column shows what US hospital labs commonly run; your own menu depends on volume, instrument and send-out arrangements.
| Organism | Clinical isolate test | Mechanism or confirmation | Screening test | Counted in reports as |
|---|---|---|---|---|
| MRSA | Cefoxitin or oxacillin on routine AST | mecA PCR or PBP2a latex when needed | Nasal PCR or chromogenic culture | Oxacillin or cefoxitin resistant S. aureus |
| VRE | Vancomycin on routine AST | vanA or vanB PCR on some platforms | Rectal or perirectal culture or PCR | Vancomycin resistant Enterococcus |
| ESBL type Enterobacterales | Ceftriaxone, cefotaxime, ceftazidime on AST | ESBL confirmation optional under current breakpoints | Rarely screened in US acute care | Third generation cephalosporin resistant |
| CRE | Carbapenems on AST | mCIM or eCIM, then KPC, NDM, VIM, IMP, OXA-48 PCR | Rectal screen during outbreaks or by state rule | Carbapenem resistant Enterobacterales |
| CRPA | Carbapenems on AST | Carbapenemase testing, often at a public health lab | Not routine | Carbapenem resistant P. aeruginosa |
| CRAB | Carbapenems on AST | Often sent to a public health lab | Outbreak screening | Carbapenem resistant Acinetobacter |
What test does a lab need for CRE?
A lab needs carbapenem susceptibility on every Enterobacterales isolate and a carbapenemase test on the ones that are resistant. mCIM is the low cost phenotypic option described in CLSI M100; rapid PCR panels name the gene. CDC asks labs to identify carbapenemase producers because they spread between patients, and the CDC Antimicrobial Resistance Laboratory Network tests isolates a hospital lab cannot.
Do labs still need ESBL confirmation tests?
Not for treatment reporting, in most US labs. Since CLSI lowered the cephalosporin breakpoints for Enterobacterales in 2010, the lab reports the interpretation directly and ESBL confirmation is optional. Many programs still want an ESBL count for infection control, so they count third generation cephalosporin resistant isolates instead. That proxy is what most hospital MDRO reports call ESBL.
Where MDRO reporting breaks down
Once the tests are running, the infection preventionist needs four numbers every quarter: how many patients had each MDRO, on which units, out of how many tested, and whether that is higher than last quarter. Most community hospitals still produce those numbers by hand. Someone runs a line list from the laboratory system, removes repeat isolates from the same patient, sorts by unit, and counts. When the line list includes every isolate rather than the first per patient, one long-stay patient with six positive cultures looks like a cluster.
The second failure is the denominator. A CRE rate means carbapenem resistant isolates divided by Enterobacterales tested against a carbapenem, not divided by all isolates. Spreadsheets drift on this, and a rate that changes because the denominator changed looks the same in a committee slide as a real rise. The third failure is timing: the report is assembled once a year, so a quarter with a jump is noticed months later.
- Repeat isolates from the same patient counted as separate cases
- Rates divided by all isolates instead of isolates tested against the marker drug
- Unit names that changed during the year split one ward into two rows
- Small denominators shown as percentages, so 2 of 5 looks like a 40 percent problem
A worked example from one year of results
A 160 bed hospital lab exports 12 months of final susceptibility results, 18,400 rows covering 3,050 isolates. After keeping the first isolate per patient per organism, 2,280 isolates remain. Of 214 Staphylococcus aureus isolates tested against oxacillin or cefoxitin, 81 are resistant, an MRSA proportion of 37.9 percent. Of 1,120 Enterobacterales tested against a carbapenem, 9 are resistant, 0.8 percent, and 7 of the 9 came from the medical ICU and the step-down unit next to it.
By quarter the CRE count reads 1, 1, 2 and 5. That last quarter is the one the committee needs to see while it is happening, together with whether the 5 isolates went for carbapenemase testing. Counted from the raw line list instead, the same year shows 14 CRE isolates, because two patients had repeat positive cultures. These figures are illustrative arithmetic, not data from a customer.
How the results reach NHSN and the committee
NHSN LabID event reporting for MRSA bacteremia and C. difficile is required of most acute care hospitals through CMS programs, and many hospitals also submit MDRO LabID events for other organisms under state rules or by choice. Those submissions are made by the infection preventionist or through a surveillance platform, from positive results that meet the NHSN definitions. The committee report is broader: every MDRO, by unit, by quarter, with the trend. Which platforms automate NHSN submission and what they cost is compared in best MDRO surveillance software for community hospitals.
Software that reports MDRO results from your lab export
Antimicrobe reads the susceptibility export your laboratory system already produces and counts MRSA, VRE, third generation cephalosporin resistant Enterobacterales, CRE, CRPA and CRAB from the S, I and R results the lab reported. It keeps the first isolate per patient, divides by isolates actually tested against the marker drug, marks rates on fewer than 30 isolates as too few, and lays the counts out by quarter with a flag when a quarter crosses the threshold you set. MDRO watch and unit cuts are on the Stewardship plan at $749 a month; the cumulative antibiogram alone is on the Lab plan at $249 a month.
It does not run or interpret bench tests, detect carbapenemase genes or submit to NHSN. For the organisms that matter most, the carbapenem side is covered on carbapenem resistant organisms reporting, the cephalosporin side on ESBL antibiogram software, and the MRSA side on MRSA antibiogram software. If the question is broader than organisms, antibiotic surveillance software separates use tracking from resistance tracking.
Questions to settle before you add a test
- Will the result change a treatment or isolation decision, or only a count?
- Does the state require reporting of this organism or mechanism, and to whom?
- Which isolates go to the public health laboratory instead of being tested in house?
- Who turns the results into a quarterly count, and how many hours does it take today?
- Does the export from your laboratory system include unit and specimen source on every row?
Related on this site: infection prevention software for MDRO tracking, MRSA tracking software for infection prevention, antibiogram software for microbiology labs.